A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
← catalyst calendarSponsored by Exelixis (industry) · EXEL — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
247actual
Sites
49
Countries
Australia, Canada, Croatia +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2015-02-25 | actual | When the study began enrolling |
| Primary completion | 2020-07-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2035 | estimated | The whole study's end, after follow-up |
| First posted | 2013-07-11 | estimated | When this record first appeared on the registry |
| Results posted | 2025-09-02 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-09-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Medullary Thyroid Cancer
Interventions
- Drug: Cabozantinib (XL184) 140 mg
- Drug: Cabozantinib (XL184) 60 mg
- Drug: Placebo tablet
- Drug: Placebo capsule
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS) Per Blinded Independent Radiology Committee (BIRC) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
measured Median time of follow-up (from the date of randomization of the first participant through primary data cut off [15 July 2020]) was 30.2 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2018-06-14 · 1.5 MB · Prot_000.pdf
Statistical Analysis Planposted 2020-06-02 · 1017 KB · SAP_001.pdf
Publications
- PMID 35403447 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed